Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTAMA in head and neck plaque psoriasis
NCT05789576Phase 4Completed
- Sponsor
- Organon & Co.
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tapinarof in plaque psoriasis, sponsored by Organon & Co. Primary endpoint: Percentage of Participants Who Achieve a Target Lesion Physician Global Assessment (PGA) Score in the Head and Neck Region of Clear (0) or Almost Clear (1) With a ≥ 2-grade Improvement at 12 weeks. Started Mar 2023; status: completed.
02
Drugs
tapinarof
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05789576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05789576.